Takeda Pharmaceutical Company has acquired Nycomed in a deal worth €9.6 million on a cash-free, debt-free basis.

The combined company will be commercially active in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Current Takeda Executive Vice President of International Operations, Dr Frank Morich, has been appointed as CEO of Nycomed.

Yasuchika Hasegawa, President and CEO of Takeda, said: “Partnering the two organisations will have complementary effects and further increase our potential to become a truly global pharmaceutical company.”

Dr Morich said that the combined company’s pharmaceutical market will cover more than 70 countries, with a presence in Japan, North America, Europe and Asia.

“I look forward to bringing Takeda and Nycomed together to ensure we can achieve enhanced revenue, growth and diversification, while maintaining the strong momentum of both companies,” he said.

Share this article: